https://ascopubs.org/doi/full/10.1200/JCO.18.01295
Vol. 37, No. 13, May 1, 2019 pages 1062-9
What an interesting read. The control arm of METASTATIC pancreatic cancer using FOLFIRINOX had a median survival of 14.4 months.
Not looking for Oncosil's argument that median survival would've been 9-11 months for LOCAL pancreatic cancer had they incorporated a control arm in the trial design.
I wonder if the tome Oncosil wrote included that one.
- Forums
- ASX - By Stock
- OSL
- Ann: Positive Regulatory Updates
OSL
oncosil medical ltd
Add to My Watchlist
2.30%
!
$1.11

Ann: Positive Regulatory Updates, page-45
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.11 |
Change
0.025(2.30%) |
Mkt cap ! $20.89M |
Open | High | Low | Value | Volume |
$1.09 | $1.11 | $1.09 | $26.73K | 24.35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6807 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.12 | 6617 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6807 | 1.110 |
1 | 4500 | 1.100 |
2 | 10900 | 1.080 |
2 | 4000 | 1.070 |
1 | 77 | 1.065 |
Price($) | Vol. | No. |
---|---|---|
1.120 | 6617 | 1 |
1.140 | 5000 | 1 |
1.145 | 5000 | 1 |
1.150 | 6938 | 1 |
1.180 | 5000 | 1 |
Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |